GH Research Reports Strong Phase 2b/2a Data for GH001 in Treatment-Resistant Depression, Postpartum Depression, and Bipolar II
Summary
GH Research announced positive results from its GH001 clinical trials, demonstrating significant efficacy and a favorable safety profile in Phase 2b for Treatment-Resistant Depression and Phase 2a for Postpartum Depression and Bipolar II Disorder with Major Depressive Episode.
Key Events
-
Phase 2b TRD Trial Met Primary Endpoint
GH001 achieved a significant reduction in MADRS total score from baseline to Day 8 (-15.5 vs placebo, P<0.0001) in patients with Treatment-Resistant Depression (TRD). The trial reported a 60.0% response rate and 57.5% remission rate at Day 8, with 73% of OLE completers maintaining remission at 6 months.
-
Strong Phase 2a PPD Results
In the Phase 2a trial for Postpartum Depression (PPD), GH001 was associated with significant MADRS reductions, with all 10 patients achieving remission (MADRS total score ≤10) by Day 8. Patients also showed a 56% improvement in maternal functioning, and mebufotenin was rapidly eliminated from breastmilk.
-
Anhedonia Improvement Across Indications
GH001 demonstrated rapid and clinically meaningful improvements in anhedonia symptoms across all three patient populations: TRD, PPD, and Bipolar II Disorder with Major Depressive Episode (BDII + MDE). These improvements were sustained at Month 6 in the TRD open-label extension.
-
Favorable Safety and Tolerability Profile
GH001 was generally well tolerated across all trials, with most treatment-emergent adverse events (TEAEs) being mild or moderate. No treatment-related serious TEAEs or events of suicidal intent or behavior were reported. The median duration of psychoactive effects was 11 minutes, with patients discharge-ready within 1 hour post-dose at 99% of visits.
Analysis
This 6-K filing presents highly positive clinical trial results for GH001 across multiple depressive disorders, significantly de-risking the asset and advancing GH Research's pipeline. The Phase 2b data in Treatment-Resistant Depression (TRD) met its primary endpoint with robust efficacy and sustained remission, which is critical for a large and underserved patient population. The Phase 2a data in Postpartum Depression (PPD) showed exceptional efficacy, with all patients achieving remission, alongside favorable maternal functioning and breastmilk elimination profiles. Consistent improvement in anhedonia across all indications further strengthens GH001's therapeutic potential. The overall well-tolerated safety profile, short psychoactive effects, and rapid discharge readiness are key advantages for patient adoption and regulatory approval. These results provide strong momentum for subsequent pivotal trials and could substantially impact the company's valuation and market position in the psychedelic-assisted therapy space.
At the time of this filing, GHRS was trading at $16.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $7.98 to $20.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.